Skip to main content
SpringerLink
Log in

Radioguided Surgery of Neuroendocrine Tumors

  • Chapter
Radioguided Surgery

Abstract

Neuroendocrine tumors constitute a heterogeneous group of neoplasms that have been postulated to originate from a common precursor cell population (1). This kind of tumor can occur sporadically or in a familial context of autosomally inherited syndromes, such as multiple endocrine neoplasms (2),(3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rindi G, Villanacci V, Ubiali A, et al. Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis. Expert Rev Mol Diagn. 2001;1:323–333.

    CAS  PubMed  Google Scholar 

  2. Calender A. Molecular genetics of neuroendocrine tumors. Digestion. 2000;62(suppl 1):3–18.

    CAS  PubMed  Google Scholar 

  3. Calender A, Vercherat C, Gaudray P, et al. Deregulation of genetic pathways in neuroendocrine tumors. Ann Oncol. 2001;12(suppl 2):S3–S11.

    PubMed  Google Scholar 

  4. Ahlman H, Wangberg B, Jansson S, et al. Interventional treatment of gastrointestinal neuroendocrine tumors. Digestion. 2000;62(suppl 1):59–68.

    PubMed  Google Scholar 

  5. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumors. 2nd ed. Heidelberg: World Health Organization; 2000.

    Google Scholar 

  6. Solcia E, Capella C, Fiocca R, et al. The gastropancreatic endocrine system and related tumors. Gastroenterol Clin North Am. 1989;4:671–693.

    Google Scholar 

  7. Lamberts SW, Hofland LJ, Nobels FR. Neuroendocrine tumor markers. Front Neuroendocrinol. 2001;22:309–339.

    CAS  PubMed  Google Scholar 

  8. Eriksson B, Oberg K, Stridsberg M. Tumor markers in neuroendocrine tumors. Digestion. 2000;62(suppl 1):33–38.

    CAS  PubMed  Google Scholar 

  9. Reubi JC, Maurer R. Autoradiographic mapping of somatostatin receptors in the rat CNS and pituitary. Neuroscience. 1985;15:1183–1193.

    CAS  PubMed  Google Scholar 

  10. Reubi JC, Laissue J, Waser B, et al. Expression of somatostatin receptors in normal, inflamed and neoplastic human gastrointestinal tissues. Ann N Y Acad Sci. 1994;733:122–137.

    CAS  PubMed  Google Scholar 

  11. Yamada Y, Post SR, Wang K, et al. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci USA. 1992;89:251–255.

    CAS  PubMed  Google Scholar 

  12. Reubi JC, Schaer JC, Laissue J, et al. Somatostatin receptors and their subtypes in human tumors and in peritumoral vessels. Metabolism. 1996;458(suppl 1):39–41.

    Google Scholar 

  13. Adams S, Baum RP, Hertel A, et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med. 1998;39:1155.

    CAS  PubMed  Google Scholar 

  14. Öhrvall U, Westlin JE, Nilsson S, et al. Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy. Cancer. 1997;80:2490–2494.

    PubMed  Google Scholar 

  15. Benjegård SA, Forssell-Aronsson E, Wängberg B, Skånberg J, Nilsson O, Ahlman H. Intraoperative tumour detection using 111In-DTPA-D-Phe1-octreotide and a scintillation detector. Eur J Nucl Med. 2001;28:1456–1462.

    PubMed  Google Scholar 

  16. Reubi JC, Torhorst J. The relationship between somatostatin, epidermal growth factor and steroid hormone receptors in breast cancer. Cancer. 1989;64:1254–1260.

    CAS  PubMed  Google Scholar 

  17. Quazzani L, Reubi JC, Volle GE, et al. Evaluation of somatostatin biosynthesis, somatostatin receptors, and tumor growth in murine medullary thyroid carcinoma. Eur J Endocrinol. 1994;131:522–530.

    Google Scholar 

  18. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993:20:716–731.

    CAS  PubMed  Google Scholar 

  19. Wiseman GA, Kvols LK. Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues. Semin Nucl Med. 1995;25:272–278.

    CAS  PubMed  Google Scholar 

  20. Adams S, Baum RP, Rink T, et al. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med. 1998;25:79–83.

    CAS  PubMed  Google Scholar 

  21. Sundin A, Eriksson B, Bergström M, et al. PET in the diagnosis of neuroendocrine tumors. Ann N Y Acad Sci. 2004;1014;246–257.

    CAS  PubMed  Google Scholar 

  22. Eriksson B, Bergström M, Sundin A, et al. The role of PET in localization of neuroendocrine tumors and adrenocortical tumors. Ann N Y Acad Sci. 2002;970;159–169.

    CAS  PubMed  Google Scholar 

  23. Wiedenmann B, Jensen RT, Mignon M, et al. Preo perative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop. World J Surg. 1998 22 309–318.

    CAS  PubMed  Google Scholar 

  24. Mignon M. Natural history of neuroendocrine enteropancreatic tumors. Digestion. 2000;63:51–58.

    Google Scholar 

  25. Gulec SA, Mountcastle TS, Frey D, et al. Cytoreductive surgery in patients with advanced-stage carcinoid tumors. Am Surg. 2002;68:667–671.

    PubMed  Google Scholar 

  26. Norton JA, Fraker DL, Alexander HR, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341:635–644.

    CAS  PubMed  Google Scholar 

  27. Arnold R. Medical treatment of metastasizing carcinoid tumors. World J Surg. 1996;20:203–207.

    CAS  PubMed  Google Scholar 

  28. Makridis C, Oberg K, Juhlin C, et al. Surgical treatment of mid-gut carcinoid tumors. World J Surg. 1990;14:377–385.

    CAS  PubMed  Google Scholar 

  29. Schneebaum S, Even-Sapir E, Meir C, et al. Clinical applications of gamma-detection probes-radioguided surgery. Eur J Nucl Med. 1999;26:S26–S35.

    CAS  PubMed  Google Scholar 

  30. Colton CL, Hardy JG. Evaluation of a sterilizable radiation probe as an aid to the surgical treatment of osteoid osteoma. J Bone Joint Surg Am. 1981;65:1019–1022.

    Google Scholar 

  31. Sutton R, Doran HE, Williams EM, et al. Surgery for mid-gut carcinoid. Endocr Relat Cancer. 2003;10:469–481.

    CAS  PubMed  Google Scholar 

  32. Memon MA, Nelson H. Gastrointestinal carcinoid tumors: current management strategies. Dis Colon Rectum. 1997;40:1101–1118.

    CAS  PubMed  Google Scholar 

  33. Marsh DJ, Learoyd DL, Robinson BG. Medullary thyroid carcinoma: recent advances and management update. Thyroid. 1995;5:407–424.

    CAS  PubMed  Google Scholar 

  34. Moley JF. Medullary thyroid cancer. Surg Clin North Am. 1995;75:405–420.

    CAS  PubMed  Google Scholar 

  35. Raue F. German medullary thyroid carcinoma/multiple endocrine neoplasia registry. German MTC/MEN Study Group. Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2. Langenbecks Arch Surg. 1998;383:334–336.

    CAS  PubMed  Google Scholar 

  36. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139–1148.

    CAS  PubMed  Google Scholar 

  37. Schröder S, Bocker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinoma. Cancer. 1988;62:806–816.

    Google Scholar 

  38. Gordon PR, Huvos AG, Strong EW. Medullary carcinoma of the thyroid gland. A clinicopathologic study of 40 cases. Cancer. 1973;31:915–924.

    CAS  PubMed  Google Scholar 

  39. Woolner LB, Beahrs OH, Black BM, et al. Long-term survival rates. In: Hedinger CHR, ed. Thyroid Cancer. Berlin, Heidelberg, New York: Springer; 1969:326–330.

    Google Scholar 

  40. Grauer A, Blind E. Tumor markers for medullary thyroid carcinoma. Rec Results Cancer. 1992;125:55–89.

    CAS  Google Scholar 

  41. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d’Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab. 2000;85:919–922.

    CAS  PubMed  Google Scholar 

  42. Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the α-subunit of glycoprotein hormones. J Clin Endocrinol Metab. 1997;82:2622–2628.

    CAS  PubMed  Google Scholar 

  43. Wahl RA, Röher AD. Surgery of C cell carcinoma of the thyroid. Prog Surg. 1988;19:100–112.

    Google Scholar 

  44. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med. 2003;253:616–626.

    CAS  PubMed  Google Scholar 

  45. Giuffrida D, Gharib H. Current diagnosis and management of medullary thyroid carcinoma. Ann Oncol. 1998;9:695–701.

    CAS  PubMed  Google Scholar 

  46. Frank-Raue K, Raue F, Buhr HJ, et al. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: high sensitivity of selective venous catheterization. Thyroid. 1992;2:113–117.

    CAS  PubMed  Google Scholar 

  47. Gotthardt M, Battmann A, Hoffken H, et al. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature. Nucl Med Commun. 2004;25:439–443.

    CAS  PubMed  Google Scholar 

  48. Shapiro B, Sisson JC, Shulkin BL, et al. The current status of metaiodobenzylguanidine and related agents for the diagnosis of neuroendocrine tumors. Q J Nucl Med. 1995;39:3–8.

    CAS  PubMed  Google Scholar 

  49. Adams S, Acker P, Lorenz M, et al. Radioisotope-guided surgery in patients with pheochromocytoma and recurrent medullary thyroid carcinoma. Cancer. 2001;92:263–270.

    CAS  PubMed  Google Scholar 

  50. Dörr U, Frank-Raue K, Raue F, et al. The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma. Nucl Med Commun. 1993;14:439–445.

    PubMed  Google Scholar 

  51. Kwekkeboom DJ, Lamberts SWJ, Reubi JC, et al. Tumor localization using 111In-octreotide scintigraphy. Eur J Nucl Med. 1992;19:599.

    Google Scholar 

  52. Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med. 1996;37:912–916.

    CAS  PubMed  Google Scholar 

  53. Adams S, Baum RP, Hertel A, et al. Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med. 1998;25:1277–1283.

    CAS  PubMed  Google Scholar 

  54. Reubi JC, Krenning E, Lamberts SWJ, et al. In vitro detection of somatostatin receptors in human tumors. Digestion. 1993;54:76–83.

    PubMed  Google Scholar 

  55. Kwekkeboom DJ, Reubi JC, Lamberts SW, et al. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1993;76:1413–1417.

    CAS  PubMed  Google Scholar 

  56. Rufini V, Salvatori M, Garganese MC, et al. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays. 2000;25:273–282.

    CAS  PubMed  Google Scholar 

  57. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999;229:880–887.

    CAS  PubMed  Google Scholar 

  58. Scollo C, Baudin E, Travagli JP, et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab. 2003;88:2070–2075.

    CAS  PubMed  Google Scholar 

  59. Inoue T, Tamaki Y, Sato Y, et al. Three-dimensional ultrasound imaging of breast cancer by a real-time intraoperative navigation system. Breast Cancer. 2005;12:122–129.

    PubMed  Google Scholar 

  60. Otha H, Tsuji T, Endo K, et al. SPECT images using 99mTc(V)-DMSA in lung metastasis of osteosarcoma. Ann Nucl Med. 1989;3:37–40.

    Google Scholar 

  61. Ercan MT, Gulaldi NC, Unsal IS, et al. Evaluation of 99mTc(V)-DMSA for imaging inflammatory lesions. An experimental study. Ann Nucl Med. 1996;10:419–423.

    CAS  PubMed  Google Scholar 

  62. Behr TM, Gratz S, Munz DL, et al. Anti-CEA antibodies versus octreotide for the detection of metastatic medullary thyroid cancer: are CEA and somatostatin-receptorexpression prognostic factors? J Nucl Med. 1997;38:9P.

    Google Scholar 

  63. De Groot JW, Links TP, Jager PL, et al. Impact of 18Ffluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol. 2004;11:786.

    PubMed  Google Scholar 

  64. Bockisch A, Brandt-Mainz K, Gorges R, et al. Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca. 2003;30:22–25.

    CAS  PubMed  Google Scholar 

  65. Goldstein RE, O’Neill Jr JA, Holcomb III GW, et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg. 1999;229:755–764.

    CAS  PubMed  Google Scholar 

  66. Peppercorn PD, Grossman AB, Reznek RH. Imaging of incidentally discovered adrenal masses. Clin Endocrinol. 1998;48:379–388.

    CAS  Google Scholar 

  67. Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med. 1994;21:561–581.

    CAS  PubMed  Google Scholar 

  68. Pacak K, Linehan WM, Eisenhofer G, et al. Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med. 2001;134:315–329.

    CAS  PubMed  Google Scholar 

  69. Ricard M, Tenenbaum F, Schlumberger M, et al. Intraoperative detection of pheochromocytoma with iodine-125 labelled metaiodobenzylguanidine: a feasibility study. Eur J Nucl Med. 1993;20:426–430.

    CAS  PubMed  Google Scholar 

  70. Kaltsas G, Korbonits M, Heintz E, et al. Comparison of somatostatin analogue and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab. 2001;86:895–902.

    CAS  PubMed  Google Scholar 

  71. Rolleman E, Krenning EP, van Gameren A, et al. Uptake of 111In-DTPA-Octreotide in the rat kidney is inhibited by colchicine and not by fructose. J Nucl Med. 2004;45:709–713.

    CAS  PubMed  Google Scholar 

  72. Neumann HP, Berger DP, Sigmund G, et al. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med. 1993;329:1531–1538.

    CAS  PubMed  Google Scholar 

  73. Pacak K, Goldstein DS, Doppman JL, et al. A “pheo” lurks: novel approaches for locating occult pheochromocytoma. J Clin Endocrinol Metab. 2001;86:3641–3646.

    CAS  PubMed  Google Scholar 

  74. Proye CAG, Lokey JS. Current concepts in functioning endocrine tumors of the pancreas. World J Surg. 2004:28;1231–1238.

    PubMed  Google Scholar 

  75. Pederzoli P, Falconi M, Bonora A, et al. Cytoreductive surgery in advanced endocrine tumours of the pancreas. Ital J Gastroenterol Hepatol. 1999;31:S207–S212.

    PubMed  Google Scholar 

  76. Jensen RT Gastrointestinal endocrine tumors. Gastrinoma. Baillieres Clin Gastroenterol. 1996;10:603–643.

    CAS  PubMed  Google Scholar 

  77. Viola KV, Sosa JA. Current advances in the diagnosis and treatment of pancreatic endocrine tumors. Curr Opin Oncol. 2005;17:24–27.

    CAS  PubMed  Google Scholar 

  78. Bansal R, Tiemey W, Carpenter S, et al. EUS should play a primary role in preoperative localization of pancreatic neuroendocrine tumors. Gastrointest Endosc. 1999;49:19–25.

    CAS  PubMed  Google Scholar 

  79. Vinik AI, Moattari AR. Treatment of endocrine tumors of the pancreas. Endocrinol Metab Clin North Am. 1989;18:483–518.

    CAS  PubMed  Google Scholar 

  80. Scott BA, Gatenby RA. Imaging advances in the diagnosis of endocrine neoplasia. Curr Opin Oncol. 1998;10:37–42.

    CAS  PubMed  Google Scholar 

  81. Service FJ, McMahon MM, O’Brien PC, et al. Functioning insulinoma: incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66:711–719.

    CAS  PubMed  Google Scholar 

  82. Grant CS. Gastrointestinal endocrine tumors. Insulinoma. Baillieres Clin Gastroenterol. 1996;10:645–671.

    CAS  PubMed  Google Scholar 

  83. Service FJ. Classification of hypoglycemic disorders. Endocrinol Metab Clin North Am. 1999;28:501–517.

    CAS  PubMed  Google Scholar 

  84. Erickson D, Kudva YC, Ebersold MJ, et al. Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients. J Clin Endocrinol Metab. 2001;86:5210–5216.

    CAS  PubMed  Google Scholar 

  85. Heij HA, Rutgers EJ, de Kraker J, et al. Intraoperative search for neuroblastoma by MIBG and radioguided surgery with the gamma detector. Med Pediatr Oncol. 1997;28:171–174.

    CAS  PubMed  Google Scholar 

  86. Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg. 2001;136:49–54.

    CAS  PubMed  Google Scholar 

  87. Wolfe MM, Jensen RT. Zollinger-Ellison syndrome. Current concepts in diagnosis and management. N Engl J Med. 1987;317:1200–1209.

    CAS  PubMed  Google Scholar 

  88. Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery. 1988;104:1046–1053.

    CAS  PubMed  Google Scholar 

  89. Hirschowitz BI, Griffith J, Pellegrin D, Cummings OW. Rapid regression of enterochromaffin-like cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology. 1992;102:1409–1418.

    CAS  PubMed  Google Scholar 

  90. Akerstrom G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg. 1996;20:173–182.

    CAS  PubMed  Google Scholar 

  91. Norton JA, Alexander HR, Fraker DL, Venzon DJ, Gibril F, Jensen RT. Comparison of surgical results in patients with advanced and limited disease with multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome. Ann Surg. 2001;234:495–506.

    CAS  PubMed  Google Scholar 

  92. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32.

    PubMed  Google Scholar 

  93. Soga J. Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases. J Exp Clin Cancer Res. 2003;22:349–363.

    CAS  PubMed  Google Scholar 

  94. Zyromski NJ, Kendrick ML, Nagorney DM, et al. Duodenal carcinoid tumors: how aggressive should we be? J Gastrointest Surg. 2001;5:588–593.

    CAS  PubMed  Google Scholar 

  95. Norton JA, Cromack DT, Shawher TH, et al. Intraoperative ultrasonographic localization of islet cell tumors. Ann Surg. 1988;207:160–168.

    CAS  PubMed  Google Scholar 

  96. Adams S, Baum RP, Wenisch HJC, et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med. 1998;39:1155–1160.

    CAS  PubMed  Google Scholar 

  97. Schirner WJ, O’Dorisio TM, Schirner TP, et al. Intraoperative localization of neuroendocrine tumors with 125ITYR3-octreotide and a hand-held gamma detecting probe. Surgery. 1993;114:745–752.

    Google Scholar 

  98. Öhrvall U, Westlin JE, Nilsson S, et al. Intraoperative gamma detection reveals abdominal endocrine tumors more efficiently than somatostatin receptor scintigraphy. Cancer. 1997;80:2490–2494.

    PubMed  Google Scholar 

  99. Lebtahi R, Cadiot L, Sarda L, et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors. J Nucl Med. 1997;38:853–858.

    CAS  PubMed  Google Scholar 

  100. Ind TE, Granowska M, Britton KE, et al. Preoperative radioimmunodetection of ovarian carcinoma using a hand-held gamma detection probe. Br J Cancer. 1994;70:1263–1266.

    CAS  PubMed  Google Scholar 

  101. Adams S, Baum RP, Adams M, et al. Untersuchungen zur prä-und intraoperativen Lokalisation von neuroendokrinen Tumoren. Acta Med Austriaca. 1997;2:81–86.

    Google Scholar 

  102. Burke AP, Thomas RM, Elsayed AM, Sobin LH. Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases. Cancer. 1997;79:1086–1093.

    CAS  PubMed  Google Scholar 

  103. Falconi M, Bettini R, Scarpa A, Capelli P, Pederzoli P. 2001 Surgical strategy in the treatment of gastrointestinal neuroendocrine tumours. Ann Oncol. 12(suppl 2):S101–S103.

    PubMed  Google Scholar 

  104. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934–959.

    PubMed  Google Scholar 

  105. Hanson HW, Feldman JM, Binder RA, et al. Carcinoid tumors: iodine-131 MIBG scintigraphy. Radiology. 1989;17:699–703.

    Google Scholar 

  106. Fischer M, Kamanbroo D, Sonderkamp H. Scintigraphic imaging of carcinoid tumors with J-131-metaiodobenzylguanidine. Lancet. 1984;135:657–662.

    Google Scholar 

  107. Ricke J, Klose KJ, Mignon M, et al. Standardization of imaging in neuroendocrine tumors: results of a European Delphi process. Eur J Radiol. 2001;37:8–17.

    CAS  PubMed  Google Scholar 

  108. Ganim RB, Norton JA. Recent advances in carcinoid pathogenesis, diagnosis, and management. Surg Oncol. 2000;9:173–179.

    CAS  PubMed  Google Scholar 

  109. Krausz Y, Keidar Z, Kogan I, et al. SPECT/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumors. Clin Endocrinol. 2003;59:565–573.

    Google Scholar 

  110. Roggo A, Wood WC, Ottinger LW. Carcinoid tumors of the appendix. Ann Surg. 1993;217:385–390.

    CAS  PubMed  Google Scholar 

  111. Sandor A, Modlin IM. A retrospective analysis of 1570 appendiceal carcinoids. Am J Gastroenterol. 1998;93:422–428.

    CAS  PubMed  Google Scholar 

  112. Moertel CG, Weiland LH, Nagorney DM, Dockerty MB. Carcinoid tumor of the appendix: treatment and prognosis. N Engl J Med. 1987;317:1699–1701.

    CAS  PubMed  Google Scholar 

  113. Butler JA, Houshiar A, Lin F, Wilson SE. Goblet cell carcinoid of the appendix. Am J Surg. 1994;168:685–687.

    CAS  PubMed  Google Scholar 

  114. Soga J. Carcinoids of the colon and ileocecal region: a statistical evaluation of 363 cases collected from the literature. J Exp Clin Cancer Res. 1998;17:139–148.

    CAS  PubMed  Google Scholar 

  115. Soga J. Carcinoids of the rectum: an evaluation of 1271 reported cases. Surg Today. 1997 27:112–119.

    CAS  PubMed  Google Scholar 

  116. Stinner B, Kisker O, Zielke A, Rothmund M. Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum. World J Surg. 1996;20:183–188.

    CAS  PubMed  Google Scholar 

  117. Koura AN, Giacco GG, Curley SA, Skibber JM, Feig BW, Ellis LM. Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival. Cancer. 1997 79:1294–1298.

    CAS  PubMed  Google Scholar 

  118. Sauven P, Ridge JA, Quan SH, Sigurdson ER. Anorectal carcinoid tumors. Is aggressive surgery warranted? Ann Surg. 1990;211:67–71.

    CAS  PubMed  Google Scholar 

  119. Woltering EA, Barrie R, O’Dorisio TM, et al. Detection of occult gastrinomas with iodine 125-labeled lanreotide and intraoperative gamma detection. Surgery. 1994;116:1139–1146.

    CAS  PubMed  Google Scholar 

  120. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy. J Nucl Med. 2000;41:1704–1713.

    CAS  PubMed  Google Scholar 

  121. Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol. 2001;12(suppl 2):S31–S36.

    PubMed  Google Scholar 

  122. Anderson CJ, Dehdashti F, Cutler PD, et al. 64Cu-TETAoctreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med. 2001;42:213–221.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, PET Center, Zentralklinik Bad Berka, Bad Berka, Germany

    Richard P. Baum MD & Stefan Adams MD

  2. Surgical Oncology Unit, University of Turin Medical School, Turin, Italy

    Sergio Sandrucci MD

Authors
  1. Richard P. Baum MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sergio Sandrucci MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefan Adams MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Regional Center of Nuclear Medicine, University of Pisa Medical School, Pisa, Italy

    Giuliano Mariani MD

  2. John Wayne Cancer Institute, Saint John’s Health Center, Santa Monica, California, USA

    Armando E. Giuliano MD (Chief of Science and Medicine) (Chief of Science and Medicine)

  3. Nuclear Medicine Service, Department of Radiology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

    H. William Strauss MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Baum, R.P., Sandrucci, S., Adams, S. (2008). Radioguided Surgery of Neuroendocrine Tumors. In: Mariani, G., Giuliano, A.E., Strauss, H.W. (eds) Radioguided Surgery. Springer, New York, NY. https://doi.org/10.1007/978-0-387-38327-9_24

Download citation

  • DOI: https://doi.org/10.1007/978-0-387-38327-9_24

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-33684-8

  • Online ISBN: 978-0-387-38327-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation